Efficacy and patient tolerability of travoprost BAK-free solution in patients with open-angle glaucoma and ocular hypertension

References

• QuiglyHABromanATThe number of people with glaucoma worldwide in 2010 and 2020Br J Ophthalmol200690326226716488940
   PubMed Web of Science ®Google Scholar
• BourneRRAWorldwide glaucoma through the looking glassBr J Ophthalmol200690325325416488934
   PubMed Web of Science ®Google Scholar
• MendrinosEShaarawyTGlaucoma surgery: toward a new global visionExpert Rev Ophthalmol20072149153
   Google Scholar
• World Health Organization Prevention of blindness and visual impairment. Available from: http://www.who.int/blindness/causes/priority/en/index7.html
   Google Scholar
• HeijlALeskeMCBengtssonBHymanLBengtssonBHusseinMReduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma TrialArch Ophthalmol20021201268127912365904
   PubMed Web of Science ®Google Scholar
• FriedmanDSWolfsRCO’ColmainBJPrevalence of open-angle glaucoma among adults in the United StatesArch Ophthalmol200412253253815078671
   PubMed Web of Science ®Google Scholar
• FriedmanDSJampelHDMonozBThe prevalence of open-angle glaucoma among blacks and whites 73 years or older: the Salisbury Eye Evaluation Glaucoma StudyArch Ophthalmol200612415251630
   Google Scholar
• LeePPWaltJGDoyleJJA multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucomaArch Ophthalmol2006124121916401779
   PubMed Web of Science ®Google Scholar
• KassMAHeuerDKHigginbothamEJThe ocular hypertension treatment studyArch Ophthalmol2002120670171312049574
   PubMed Web of Science ®Google Scholar
• Collaborative Normal-Tension Glaucoma Study GroupComparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressureAm J Ophthalmol19981264874979780093
   PubMed Web of Science ®Google Scholar
• LichterPRMuschDCGillespieBWInterim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study (CIGTS) comparing initial treatment randomized to medications or surgeryOphthalmology20011081943195311713061
   PubMed Web of Science ®Google Scholar
• van der ValkRWebersCASchoutenJSZeegersMPHendrikseFPrinsMHIntraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trialsOphthalmology20051121177118515921747
   PubMed Web of Science ®Google Scholar
• LimKSNauCBO’ByrneMMMechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects: a crossover studyOphthalmology2008115579079518452763
   PubMed Web of Science ®Google Scholar
• KonstasAGPKozobolisVPKatsimprisIEfficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patientsOphthalmology2007114465365717197028
   PubMed Web of Science ®Google Scholar
• AliFSAkpekEKGlaucoma and dry eyeOphthalmology20091166123219486808
   PubMed Web of Science ®Google Scholar
• ShaumbergDASullivanDABuringJEPrevalence of dry eye syndrome among US womenAm J Ophthalmol200313631832612888056
   PubMed Web of Science ®Google Scholar
• MossSEKleinRKleinBEPrevalence of and risk factors for dry eye syndromeArch Ophthalmol20001181264126810980773
   PubMed Web of Science ®Google Scholar
• McCartyCABansalAKLivingstonPMThe epidemiology of dry eye in Melbourne, AustraliaOphthalmology1998105111411199627665
   PubMed Web of Science ®Google Scholar
• ScheinODHochbergMCMunozBDry eye and dry mouth in the elderlyArch Intern Med19991591359136310386512
   PubMed Web of Science ®Google Scholar
• DoughtyMJFonnDRicheterDA patient questionnaire approach to estimating the prevalence of dry eye symptoms in patients presenting to optometric practices across CanadaOptom Vis Sci1997746246319323733
   PubMed Web of Science ®Google Scholar
• LinPYTsaiSYChengCYPrevalence of dry eye among an elderly Chinese population in Taiwan: the Shihpai Eye StudyOphthalmology20031101096110112799232
   PubMed Web of Science ®Google Scholar
• LeeAJLeeJSawS-MPrevalence and risk factors associated with dry eye symptoms: a population based study in IndonesiaBr J Ophthalmol2002861347135112446361
   PubMed Web of Science ®Google Scholar
• ShimmuraSShimazakiJTsubotaKResults of a population-based questionnaire on the symptoms and lifestyles associated with dry eyeCornea19991840841110422851
   PubMed Web of Science ®Google Scholar
• SchiffmanRMWaltJGJacobsenGUtility assessment among patients with dry eye diseaseOphthalmology20031101412141912867401
   PubMed Web of Science ®Google Scholar
• CleggJPGuestJFLehmanASmithAFThe annual cost of dry eye syndrome in France, Germany, Italy, Spain, Sweden, and the UKOphthalmic Epidemiol20061326327416877285
   PubMed Web of Science ®Google Scholar
• PerryHDDry eye disease: pathophysiology, classification, and diagnosisAm J Manag Care200814Suppl 3S79S8718452371
   PubMedGoogle Scholar
• SchmierJKCovertDWCharacteristics of respondents with glaucoma and dry eye in a national panel surveryClin Ophthalmol2009364565019997568
   PubMedGoogle Scholar
• RossiGCTinelliCPasinettiGMDry eye syndrome-related quality of life in glaucoma patientsEur J Ophthalmol200919457257919551671
   PubMed Web of Science ®Google Scholar
• NordmannJPAuzanneauNRicardSBerdeauxGVision-related quality of life and topical glaucoma treatment side-effectsHealth Qual Life Outcomes200317514667241
   PubMedGoogle Scholar
• MalvitteLMontangeTVejuxAMeasurement of inflammatory cytokines by multicytokine assay in tears of patients with glaucoma topically treated with chronic drugsBr J Ophthalmol200791293216943231
   PubMed Web of Science ®Google Scholar
• SchwartzGFTanJKotakSHyperemia-associated costs of medication changes in glaucoma patients treated initially with prostaglandin analogsJ Ocul Pharmacol Ther200925655556120028264
   PubMed Web of Science ®Google Scholar
• LeungEWMedeirosFAWeinrebRNPrevalence of ocular surface disease in glaucoma patientsJ Glaucoma20081735035518703943
   PubMed Web of Science ®Google Scholar
• FriedmanDSHahnSRGelbLDoctor-patient communication, health-related beliefs, and adherence in glaucoma results from the Glaucoma Adherence and Persistency StudyOphthalmology20081151320132718321582
   PubMed Web of Science ®Google Scholar
• FeldmanRMConjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertensionJ Ocul Pharmacol Ther200319233512648301
   PubMed Web of Science ®Google Scholar
• ReesGLeongOCrowstonJCLamoureuxELIntentional and unintentional nonadherence to ocular hypotensive treatment in patients with glaucomaOphthalmology2010117590390820153902
   PubMed Web of Science ®Google Scholar
• SchwartzGFCompliance and persistency in glaucoma follow-up treatmentCurrent Opin Ophthalmol2005162114121
   Google Scholar
• ParrishRKPalmbergPSheuWPfor XLT Study GroupA comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter studyAm J Ophthalmol2003135568870312719078
   PubMed Web of Science ®Google Scholar
• BroadwayDCChangLPTrabeculectomy, risk factors for failing and the preoperative state of the conjunctivaJ Glaucoma20011023724911442190
   PubMed Web of Science ®Google Scholar
• PisellaPJPouliquenPBaudouinCPrevalence of ocular symptoms and signs with preserved and preservative-free glaucoma medicationBr J Ophthalmol20028641842311914211
   PubMed Web of Science ®Google Scholar
• JaenenNBaudouinCPouliquenPOcular symptoms and signs with preserved and preservative-free glaucoma medicationsEur J Ophthalmol20071734134917534814
   PubMed Web of Science ®Google Scholar
• RahmanMQTejwaniDWilsonJAButcherIRamaeshKMicrobial contamination of preservative free eye drops in multiple application containersBr J Ophthalmol20069013914116424520
   PubMed Web of Science ®Google Scholar
• ScheinODHibberdPLStarchTBakerASKenyanKRMicrobial contamination of the in-use ocular medicationsArch Ophthalmol199211082851731727
   PubMedGoogle Scholar
• GeyerOBottoneEJPodosSMSchumerRAAsbellPAMicrobial contamination of medications used to treat glaucomaBr J Ophthalmol1995793763797742288
   PubMed Web of Science ®Google Scholar
• WhitsonJTVarnerDLGroveDNetlandPAGlaucoma drugs and the ocular surfaceRev Ophthalmol200613116979
   Google Scholar
• BurnsteinNLKlyceSDElectrophysiologic and morphologic effects of ophthalmic preparations on rabbit cornea epitheliumInvest Ophthalmol Vis Sci19776899911
   Google Scholar
• GassetARIshiiYKaufmanHEMillerTCytotoxicity of ophthalmic preservativesAm J Ophthalmol197471981054835060
   PubMed Web of Science ®Google Scholar
• BerdyGJAbelsonMBSmithLMGeorgeMAPreservative-free artificial tear preparations. Assessment of corneal epithelial toxic effectsArch Ophthalmol19921105285321562263
   PubMed Web of Science ®Google Scholar
• TripathiBJTripathiRCKilliSPCytotoxicity of ophthalmic preservatives on human corneal epitheliumLens Eye Toxic Res199293–43613751301792
   PubMedGoogle Scholar
• BursteinNLThe effects of topical drugs and preservatives on the tears and corneal epithelium in dry eyeTrans Ophthalmol Soc U K19851044024093898475
   PubMedGoogle Scholar
• ShawAJBallsMClothierRHBatemanNDPredicting ocular irritancy and recovery from injury using Madin-Darby canine kidney cellsToxicol In Vitro19915169174
   PubMed Web of Science ®Google Scholar
• ChampeauEJEdelahuserHFEffect of ophthalmic preservatives on the ocular surface: conjunctival and corneal uptake and distribution of benzalkonium chloride and chlorhexidine digluconateHollyFJThe Preocular Tear FilmLubbock, TXDry Eye Institute, Inc1986
   Google Scholar
• IchijimaHPetrollWMJesterJVCavanaghHDConfocal microscopic studies of living rabbit cornea treated with benzalkonium chlorideCornea1992112212251587129
   PubMed Web of Science ®Google Scholar
• YeeRWThe effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a reviewCurrent Opin Ophthalmology200718134139
   PubMed Web of Science ®Google Scholar
• de Saint JeanMBrignoleFBringuierAFBauchetAFelmannGBauduoinCEffects of benzalkonium chloride on growth and survival of Chang conjunctival cellsInvest Ophthalmol Vis Sci19994061963010067965
   PubMed Web of Science ®Google Scholar
• WilliamsDENguyenKDShapourifar-TehraniSKitadaSLeeDAEffects of timolol, betaxolol, and levobunolol on human tenon’s fibroblasts in tissue cultureInvest Ophthalmol Vis Sci199233223322411607234
   PubMed Web of Science ®Google Scholar
• BaudouinCPisellaPJFillacierKOcular surface inflammatory changes induced by topical antiglaucoma drugsOphthalmology1999106355656310080214
   PubMed Web of Science ®Google Scholar
• DebbaschCBrignoleFPisellaPJQuaternary ammoniums and other preservatives’ contribution in oxidative stress and apoptosis on Chang conjunctival cellsInvest Ophthalmol Vis Sci20014264265211222522
   PubMed Web of Science ®Google Scholar
• PisellaPJDebbaschCHamardPConjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro studyInvest Ophthalmol Vis Sci2004451360136815111589
   PubMed Web of Science ®Google Scholar
• CostagliolaCPreteADIncorvaiaCOcular surface changes induced by topical application of latanoprost and timolol: a short-term study in glaucomatous patients with and without allergic conjunctivitisGraefes Arch Clin Exp Ophthalmol200123980981411789860
   PubMed Web of Science ®Google Scholar
• LiesegangTJConjunctival changes associated with glaucoma therapy: implications for the external disease consultant and treatment of glaucomaCornea1998175745839820934
   PubMed Web of Science ®Google Scholar
• GuenounJMBaudouinCRatPIn vitro study of inflammatory potential and toxicity profile between latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cellsInvest Ophthalmol Vis Sci2005462444245015980234
   PubMed Web of Science ®Google Scholar
• GuenounJMBaudouinCRatPIn vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cellsInvest Ophthalmol Vis Sci2005404594459916303954
   PubMed Web of Science ®Google Scholar
• SkutaGLParrishRKIIWound healing in glaucoma filtering surgerySurv Ophthalmol198780624627
   Google Scholar
• HitchingsRAGriersonIClinico-pathologic correlation in eyes with failed fistulizing surgeryTrans Ophthalmol Soc U K198310384886581641
   PubMedGoogle Scholar
• BroadwayDCGriersonIO’BrienCHitchingsRAAdverse effects of topical antiglaucoma medication, II: the outcome of filtration surgeryArch Ophthalmol1994112144614547980134
   PubMed Web of Science ®Google Scholar
• KuppensEVde JongCAStolwijkTRde KreizerRJvan BestJAEffects of timolol with and without preservative on the basal tear turnover in glaucomaBr J Ophthalmol1993775905968218059
   PubMed Web of Science ®Google Scholar
• BaudouinCDetrimental effect of preservatives in eyedrops: implications for the treatment of glauocomaActa Ophthalmol20088671672618537937
   PubMed Web of Science ®Google Scholar
• YoungTLHigginbothamEJZouXFarberMDEffects of topical glaucoma drugs on fistulized rabbit conjunctivaOphthalmology199097142314272255514
   PubMed Web of Science ®Google Scholar
• LavinMJWormaldRPLMigdalCSHitchingsRAInfluence of prior therapy on the success of trabeculectomyArch Ophthalmol1990108154315482244836
   PubMed Web of Science ®Google Scholar
• JohnsonDHYoshikawaKBrubakerRFHodgeDOThe effect of long-term medical therapy on the outcome of filtration surgeryAm J Ophthalmol19941171391488116740
   PubMed Web of Science ®Google Scholar
• BaudouinCMechanisms of failure in glaucoma filtering surgery: a consequence of antiglaucomatous drugs?Int J Clin Pharmacol Res19961629419001927
   PubMedGoogle Scholar
• BaudouinCSide effects of antiglaucomatous drugs on the ocular surfaceCurr Opin Ophthalmol19967808610163327
   PubMedGoogle Scholar
• TamilvananSBenitaSThe potential of lipid emulsion for ocular delivery of lipophilic drugsEur J Pharm Biopharm20045835736815296961
   PubMed Web of Science ®Google Scholar
• Sila-OnWVardhanabhutiNOngpipattanakulBKulvanichPThe influence of physicochemical properties of preservative compounds on their distribution into various phases of oil in water submicron emulsionPDA J Pharm Sci Technol20066017218117089686
   PubMedGoogle Scholar
• SznitowskaMJanickiSDabrowskaEAGajewskaMPhysicochemical screening of antimicrobial agents as potential preservatives for submicron emulsionsEur J Pharm Sci20021548949512036725
   PubMed Web of Science ®Google Scholar
• LiangHBrignole-BaudouinFRabinovich-GuilattLReduction of quaternary ammonium-induced ocular surface toxicity by emulsions: an in vivo study in rabbitsMol Vis20081420421618347566
   PubMed Web of Science ®Google Scholar
• KaurIPLalSRanaCKakkarSSinghHOcular preservatives: associated risks and newer optionsCutan Ocul Toxicol20092839310319505226
   PubMed Web of Science ®Google Scholar
• KahookMYTravoprost Z ophthalmic solution with sofZia: clinical safety and efficacyExpert Rev Ophthalmol20072363368
   Google Scholar
• MundorfTWilliamsRWhitcupSA 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertensionJ Ocul Pharmacol Ther2003191374412648302
   PubMed Web of Science ®Google Scholar
• KatzLJTwelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertensionJ Glaucoma200211211912611912359
   PubMed Web of Science ®Google Scholar
• BaudouinCHamardPLiangHConjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long termOphthalmology2004111122186219215582072
   PubMed Web of Science ®Google Scholar
• IshibashiTYokoiNKinoshitaSComparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chlorideJ Glaucoma20031248649014646684
   PubMed Web of Science ®Google Scholar
• BaudouinCde LunardoCShort term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteersBr J Ophthalmol19988239429536878
   PubMed Web of Science ®Google Scholar
• VassCHirnCSychaTMedical interventions for primary open angle glaucoma and ocular hypertensionCochrane Database Syst Rev20074CD00316717943780
   PubMed Web of Science ®Google Scholar
• HodgeWBLachaineJSteffensenIThe efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic reviewBr J Ophthalmol20089271218156371
   PubMed Web of Science ®Google Scholar
• EyawoONachegaJLefebvrePEfficacy and safety of prostaglandin analogues in patients with predominately primary open-angle glaucoma or ocular hypertension: a meta-analysisClin Ophthalmol2009344745619684868
   PubMedGoogle Scholar
• AptelFCucheratMDenisPEfficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trialsJ Glaucoma200817866767319092464
   PubMed Web of Science ®Google Scholar
• LewisRAKatzGJWeissMJTravoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacyJ Glaucoma20071619810317224758
   PubMed Web of Science ®Google Scholar
• GodfreyDAPeplinskiLSStewartJAStewartWCA comfort comparison of travoprost BAK-free 0.004% versus lantanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertensionClin Ophthalmol2009318919419668564
   PubMedGoogle Scholar
• BaudouinCRianchoLWarnetJMBrignoleFIn vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprostInvest Ophthalmol Vis Sci20074894123412817724196
   PubMed Web of Science ®Google Scholar
• YeeRNorcomEGZhaoXCComparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture systemAdv Ther20062351151817050493
   PubMed Web of Science ®Google Scholar
• NguyenDHBeuermanRWde WeverBRosdyMThree-dimensional construct of the human corneal epithelium for in vitro toxicologySalemHKatzSAAlternatives Toxicological MethodsBoca Raton, FloridaCRC Press2003147159
   Google Scholar
• MorganRLSorensonSSCastlesTRPrediction of ocular irritation only corneal pachymetryFood Chem Toxicol1987256096133623352
   PubMed Web of Science ®Google Scholar
• Khoh-ReiterSJessenBAEvaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D modelBMC Ophthalmol20099519638217
   PubMed Web of Science ®Google Scholar
• WhitsonJTCavanagahHDLakshmanNPetrollWMAssessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chlorideAdv Ther20062366367117142200
   PubMed Web of Science ®Google Scholar
• GreenKJackMCCheeksLDetergent penetration into young and adult rabbit eyes: comparative pharmacokineticsCutan Ocul Toxicol1987689107
   Web of Science ®Google Scholar
• KahookMYNoeckerRJComparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tearsCornea20082733934318362664
   PubMed Web of Science ®Google Scholar
• CurrenRDHarbellJWIn vitro alternatives for ocular irritationEnviron Health Perspect19981064854929599696
   PubMed Web of Science ®Google Scholar
• RoggebandRYorkMPericoiMBraunWEye irritation responses in rabbit and man after single applications of equal volumes of undiluted model liquid detergent productsFood Chem Toxicol20003872773410908820
   PubMed Web of Science ®Google Scholar
• NetlandPALandryTSullivanEKfor Travoprost Study GroupTravoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertensionAm J Ophthalmol200113247248411589866
   PubMed Web of Science ®Google Scholar
• GrossRLPeaceJHSmithSEDuration of IOP reduction with travoprost BAK-free solutionJ Glaucoma20081721722218414108
   PubMed Web of Science ®Google Scholar
• HenryJCPeaceJHStewartJAStewartWCEfficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapyClin Ophthalmol2008261362119668762
   PubMedGoogle Scholar